Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)

Trial Profile

Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2018

At a glance

  • Drugs ET1402L1 CART (Primary) ; ET1402L1 CART (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Aeon Therapeutics
  • Most Recent Events

    • 05 Sep 2018 Results published in the Eureka Therapeutics Media Release
    • 05 Sep 2018 Acording to Eureka Therapeutics media release, today announced preliminary safety and clinical results from this study. The data was presented today in the late-breaking abstracts session of the CAR-TCR Summit in Boston, Massachusett.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top